Candel Therapeutics (CADL) EBIT: 2020-2023
Historic EBIT for Candel Therapeutics (CADL) over the last 4 years, with Dec 2023 value amounting to -$10.3 million.
- Candel Therapeutics' EBIT fell 27.37% to -$10.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$38.4 million, marking a year-over-year decrease of 10.57%. This contributed to the annual value of -$33.4 million for FY2024, which is 13.08% up from last year.
- Per Candel Therapeutics' latest filing, its EBIT stood at -$10.3 million for Q4 2023, which was down 16.44% from -$8.9 million recorded in Q3 2023.
- Candel Therapeutics' EBIT's 5-year high stood at -$2.3 million during Q2 2020, with a 5-year trough of -$10.3 million in Q4 2023.
- Its 3-year average for EBIT is -$8.2 million, with a median of -$8.8 million in 2022.
- Per our database at Business Quant, Candel Therapeutics' EBIT tumbled by 192.07% in 2021 and then grew by 0.23% in 2023.
- Over the past 4 years, Candel Therapeutics' EBIT (Quarterly) stood at -$6.1 million in 2020, then decreased by 26.37% to -$7.7 million in 2021, then fell by 4.66% to -$8.1 million in 2022, then declined by 27.37% to -$10.3 million in 2023.
- Its EBIT stands at -$10.3 million for Q4 2023, versus -$8.9 million for Q3 2023 and -$9.6 million for Q2 2023.